A double blind phase II study of BAY 43-9006 in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens

Trial Profile

A double blind phase II study of BAY 43-9006 in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2012

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Primary endpoint 'Stable-disease-rate' has been met according to results published in the Journal of Thoracic Oncology.
    • 01 Oct 2012 Results published in the Journal of Thoracic Oncology.
    • 31 Jul 2009 Results have been reported at the 13th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top